Analysts predict that Mallinckrodt PLC (NYSE:MNK) will report $1.72 earnings per share (EPS) for the current quarter, according to Zacks. Seven analysts have made estimates for Mallinckrodt’s earnings. The lowest EPS estimate is $1.52 and the highest is $1.89. Mallinckrodt reported earnings of $1.91 per share in the same quarter last year, which suggests a negative year over year growth rate of 9.9%. The firm is expected to issue its next quarterly earnings report before the market opens on Tuesday, February 27th.
According to Zacks, analysts expect that Mallinckrodt will report full-year earnings of $7.20 per share for the current year, with EPS estimates ranging from $7.02 to $7.41. For the next fiscal year, analysts expect that the firm will report earnings of $6.96 per share, with EPS estimates ranging from $5.78 to $7.32. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Mallinckrodt.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.17. The company had revenue of $793.90 million during the quarter, compared to analyst estimates of $808.93 million. Mallinckrodt had a return on equity of 14.79% and a net margin of 11.43%. The firm’s quarterly revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the business posted $2.04 EPS.
A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded Mallinckrodt from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. ValuEngine upgraded Mallinckrodt from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Mizuho reiterated a “hold” rating and set a $40.00 price objective on shares of Mallinckrodt in a research note on Sunday, October 15th. Canaccord Genuity set a $24.00 price objective on Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, December 26th. Finally, Goldman Sachs Group reiterated a “hold” rating on shares of Mallinckrodt in a research note on Monday, January 1st. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $44.99.
Shares of Mallinckrodt (NYSE:MNK) traded down $0.37 during mid-day trading on Wednesday, reaching $23.13. The company had a trading volume of 2,136,100 shares, compared to its average volume of 2,424,200. The stock has a market cap of $2,150.00, a price-to-earnings ratio of -1,156.50, a price-to-earnings-growth ratio of 0.44 and a beta of 1.30. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.38 and a quick ratio of 1.05. Mallinckrodt has a one year low of $19.00 and a one year high of $55.32.
In other news, Director David R. Carlucci acquired 10,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were bought at an average cost of $21.83 per share, for a total transaction of $218,300.00. Following the acquisition, the director now owns 26,020 shares in the company, valued at approximately $568,016.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Michael-Bryant Hicks acquired 7,900 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average price of $20.80 per share, for a total transaction of $164,320.00. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 30,460 shares of company stock worth $659,486. 0.53% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in Mallinckrodt by 16.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,522,330 shares of the company’s stock worth $94,255,000 after buying an additional 360,516 shares during the last quarter. HealthCor Management L.P. acquired a new position in shares of Mallinckrodt during the 2nd quarter worth approximately $107,649,000. Ameriprise Financial Inc. boosted its holdings in shares of Mallinckrodt by 2.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,987,196 shares of the company’s stock worth $74,260,000 after purchasing an additional 49,752 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of Mallinckrodt by 45.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,535,583 shares of the company’s stock worth $57,385,000 after purchasing an additional 482,591 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its holdings in shares of Mallinckrodt by 15.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,472,700 shares of the company’s stock worth $55,035,000 after purchasing an additional 200,000 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://transcriptdaily.com/2018/01/17/1118718.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.